New 2-Layer 'Lite' Bandage System from 3M Benefits Patients Less Tolerant of Compression

Building on the success of its Coban 2 layer compression system, global technology company 3M has introduced the first 2-layer 'Lite' system to deliver sustained therapeutic compression to patients unable to tolerate high resting pressures. Indicated for patients with venous ulcers, venous ulcers with an arterial component ('mixed aetiology') and lymphoedema, the Coban 2 layer Lite compression system can be safely applied in selected patients where the patient's ABPI (Ankle: Brachial Pressure Index) is equal to or greater than 0.5.

"The new Lite system effectively extends the treatment options for patients with an arterial component to their ulceration" says Professor Peter Vowden, Consultant Vascular Surgeon at Bradford Royal Infirmary. "Careful, holistic assessment of these patients is particularly important and reliance should not be placed on the ABPI alone, however clinical study[1] has demonstrated that when applied at full stretch, the system delivers an average supine sub-bandage pressure of 28mmHg and is comfortable and well tolerated, with no evidence of pressure-related skin damage."

In a series of case studies[2], 100% of patients demonstrated wound healing or wound reduction after six weeks of treatment with the Coban 2 layer Lite system, including the healing of an ulcer of ten years duration in a 91 year old patient. With good static and dynamic stiffness, the Coban 2 layer Lite system delivers up to 7 days wear time with minimal bandage slippage.

Importantly, its low profile enables the wearing of normal footwear, helping to improve patient mobility and quality of life whilst reducing the risk of social isolation.

“With the launch of the Lite system, 3M can now offer health care professionals an effective choice of 2-layer compression therapy,” says Angela Mears, Senior Marketing Executive, Skin & Wound Care business. “We were delighted with the feedback we received from patients about its comfort, many of whom had previously been treated with other compression systems.“

ENDS

Notes to Editors

1. For further information, please contact Rosalind Smith, Public Relations Manager, 3M Health Care on (01509) 613009 or email rsmith@mmm.com

2. 3M and Coban are trademarks of the 3M Company.

3. References:
   1. Compression therapy in patients with peripheral arterial occlusive disease: A prospective clinical study with the 3M™ Coban™ 2 Layer Lite Compression System for ABPI greater than or equal to 0.5. Jünger M., Haase H., Ladwig A. Schwenke L. et al. Available on request from 3M.
   2. Data on file, 3M

4. About 3M – practical and ingenious solutions that help our customers succeed

   3M is a $23 billion diversified technology company which, since 1902, has been creating innovative products that help make the world healthier, safer and more productive. Well known 3M brands include Scotch, Post-it, Scotchgard, Thinsulate and Scotch-Brite.

   3M employs some 75,000 people worldwide and has operations in more than 65 countries. It produces tens of thousands of innovative products for customers in dozens of

diverse markets and its 40+ technology platforms touch nearly every aspect of modern life. The company has applied its expertise in RFID (radio frequency identification) technology to map and locate underground utilities; it has used its understanding of the healthcare industry to develop innovations that help the early diagnosis of heart and lung conditions; and its range of pocket projectors are the ultimate presentation devices for business people on the go.

The UK and Ireland is home to one of the largest 3M subsidiaries outside the USA, employing more than 3,500 people across 17 locations, including 10 manufacturing sites. Products manufactured in the UK include coated abrasives, occupational health and environmental safety equipment, adhesive tapes, industrial microbiology products, drug delivery systems, high-performance coatings, secure documents and passport scanners.
www.3M.co.uk/healthcare